7 research outputs found
Analysis of surface roughness and hardness in titanium alloy machining with polycrystalline diamond tool under different lubricating modes
Reconstruction of neglected chronic tendoachilles tear healed in continuity: surgical technique
Architecture of high-strength aluminum–matrix composites processed by a novel microcasting technique
Mammographically dense human breast tissue stimulates MCF10DCIS.com progression to invasive lesions and metastasis
Controversies around epithelial–mesenchymal plasticity in cancer metastasis
Experimental evidence accumulated over decades has implicated epithelial–mesenchymal plasticity (EMP), which collectively encompasses epithelial–mesenchymal transition and the reverse process of mesenchymal–epithelial transition, in tumour metastasis, cancer stem cell generation and maintenance, and therapeutic resistance. However, the dynamic nature of EMP processes, the apparent need to reverse mesenchymal changes for the development of macrometastases and the likelihood that only minor cancer cell subpopulations exhibit EMP at any one time have made such evidence difficult to accrue in the clinical setting. In this Perspectives article, we outline the existing preclinical and clinical evidence for EMP and reflect on recent controversies, including the failure of initial lineage-tracing experiments to confirm a major role for EMP in dissemination, and discuss accumulating data suggesting that epithelial features and/or a hybrid epithelial–mesenchymal phenotype are important in metastasis. We also highlight strategies to address the complexities of therapeutically targeting the EMP process that give consideration to its spatially and temporally divergent roles in metastasis, with the view that this will yield a potent and broad class of therapeutic agents.See 'additional link' for access to a free to read version of the article.</p